

pattern has an overall accuracy of 98.8% suggesting that such invasive pattern is a useful indicator to predict the invasion of sm layer especially sm deep (sm2-3) invasion. Thus, the invasive/non-invasive pit pattern might be used to determine the ideal treatment, either endoscopic resection or surgery. In addition, the diagnostic sensitivity of the clinical pit pattern classification to properly identify the depth of invasion of flat and depressed lesions was superior to that of polypoid lesions (97.5% vs. 75.8%). For these former cases, not only MCE but also other predictive factors or diagnostic methods should be considered for diagnosis.

Some authors have reported the usefulness of endoscopic ultrasonography (EUS) particularly the advantages of high frequency ultrasound (HFUS) to diagnose the invasion depth of early colorectal cancer (27-30). Hurlstone *et al.* conducted a study to compare the two modalities (30). According to their result, HFUS was superior to MCE for determination of depth invasion (93% vs. 59%, respectively). Meanwhile, Fu *et al.* have recently reported that MCE is as accurate as EUS for preoperative staging of early colorectal cancer (31). Generally, EUS colonoscopes have a rigid tip that makes it difficult to always reach the cecum when compared with conventional ones. Regarding cost-effectiveness and time-consuming issues, EUS is not as good as MCE. Furthermore, Uno *et al.* (32) and Kobayashi *et al.* (33) reported the verification of the "Non-lifting sign" as one modality of depth diagnosis for colorectal cancers. In spite of the simplicity of such technique, Kobayashi *et al.* concluded that the "Non-lifting sign" could not reliably predict deeper cancerous invasion in comparison with endoscopic diagnosis.

There are some limitations in our study. First, the endoscopic diagnosis using magnification was performed after conventional endoscopic diagnosis which means endoscopists were not blinded to diagnose only with MCE images. Therefore, we could not evaluate how much MCE diagnosis exceeded compared to conventional endoscopic diagnosis. Second, since only neoplastic lesions were included in this study, it is difficult to prove the usefulness of MCE as a differential diagnostic modality between neoplastic or non-neoplastic lesions. For such distinction, however, chromoendoscopy with magnification has already been reported to be the most reliable method to determine whether a colorectal lesion is neoplastic or not (12-14). Another point worth mentioning is that all procedures were carried out by experienced examiners. This means that the effectiveness of MCE deserves revalidation studies including ideally general endoscopists. The effort necessary for learning to identify mucosal crypt patterns is important but scarcely studied. Generally, differential diagnosis by MCE is simple and easy to learn compared with depth diagnosis (m/sm1 or sm2-3) for beginners. Togashi *et al.* investigated the efficacy of magnifying colonoscopy in the differential diagnosis of colorectal polyps and also described the learning curve in their study. They reported that a minimum experience of observing 200 lesions with high-magnification was necessary to understand pit pattern diagnosis (9). In addition, we only used the optical

zoom (OZ) system, which enables a more precise magnification image than that of the electronic zoom (EZ) system. Except for a small number of institutions, the OZ system is not available in Western countries. In the near future, comparative studies between OZ and EZ should be performed to validate the usefulness of MCE.

In conclusion, the present study suggests that the diagnosis of invasive or non-invasive pit pattern observed by MCE is a highly effective *in vivo* method to predict the depth of invasion of colorectal neoplasms, and consequently a useful tool for endoscopic staging of early colorectal cancers. In the near future, multi-center trials should be performed to validate the usefulness of MCE compared to other modalities (e.g., conventional colonoscopy, EUS, non-lifting sign).

ACKNOWLEDGMENTS

We would like to express an appreciation to Dr. Sergio A. Con for assistance in editing this manuscript.

STUDY HIGHLIGHTS

What Is Current Knowledge

- *In vivo* estimation of the depth of invasion in early colorectal lesions is crucial for an adequate therapeutic strategy.
- Magnifying chromoendoscopy (MCE) has been proposed as the best method. However, there are no large-scale validation studies concerning the clinical classification of the pit pattern.

What Is New Here

- A large prospective study of 4,215 lesions conducted at the National Cancer Center Hospital has demonstrated that the clinical pit pattern (invasive/non-invasive) evaluated by MCE is a highly effective *in vivo* method to predict the depth of invasion of colorectal neoplasms.

Reprint requests and correspondence: Takahisa Matsuda, M.D., Endoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Received March 6, 2008; accepted July 25, 2008.

REFERENCES

1. Morson BC, Whiteway JE, Jones EA, et al. Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy. *Gut* 1984; 25:437-44.
2. Fujimori T, Kawamata H, Kashida H. Precancerous lesion of the colorectum. *J Gastroenterol* 2001; 36:587-94.
3. Kyzer S, Begin LR, Gordon PH, et al. The care of patients with colorectal polyps that contain invasive adenocarcinoma. *Cancer (Phila)* 1992; 70:2044-50.

4. Minamoto T, Mai M, Ogino T, et al. Early invasive colorectal carcinomas metastatic to the lymph node with attention to their nonpolypoid development. *Am J Gastroenterol* 1993;88:1035-9.
5. Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the colon and rectum. *Am J Surg Pathol* 1983;7:613-23.
6. Nusko G, Mansmann U, Partzsch U, et al. Invasive carcinoma in colorectal adenomas: Multivariate analysis of patient and adenoma characteristics. *Endoscopy* 1997;29:626-31.
7. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon. November 30 to December 1, 2002. *Gastrointest Endosc* 2003;58:S3-43.
8. Kudo S, Hirota S, Nakajima T, et al. Colorectal tumours and pit pattern. *J Clin Pathol* 1994;47:880-5.
9. Togashi K, Konishi F, Ishizuka T, et al. Efficacy of magnifying endoscopy in the differential diagnosis of neoplastic and non-neoplastic polyps of the large bowel. *Dis Colon Rectum* 1999;42:1602-8.
10. Tung SY, Wu CS, Su MY. Magnifying colonoscopy in differentiating neoplastic from nonneoplastic colorectal lesions. *Am J Gastroenterol* 2001;96:2628-32.
11. Konishi K, Kaneko K, Kurahashi T, et al. A comparison of magnifying and nonmagnifying colonoscopy for diagnosis of colorectal polyps: A prospective study. *Gastrointest Endosc* 2003;57:48-53.
12. Fu KI, Sano Y, Kato S, et al. Chromoendoscopy using indigo-carmin dye-spraying with magnifying observation. Is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions? A prospective study. *Endoscopy* 2004;36:1089-93.
13. Kato S, Fu KI, Sano Y, et al. Magnifying colonoscopy as a non-biopsy technique for differential diagnosis of non-neoplastic and neoplastic lesions. *World J Gastroenterol* 2006;12:1416-20.
14. Emura F, Saito Y, Taniguchi M, et al. Further validation of magnifying chromocolonoscopy for differentiating colorectal neoplastic polyps in a health screening center. *J Gastroenterol Hepatol* 2007;22:1722-7.
15. Tanaka S, Kaltenbach T, Chayama K, et al. High-magnification colonoscopy. *Gastrointest Endosc* 2006;64:604-13.
16. Kudo S, Tamura S, Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. *Gastrointest Endosc* 1996;44:8-14.
17. Kudo S, Kashida H, Tamura T, et al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. *World J Surg* 2000;24:1081-90.
18. Kashida H, Kudo S. Magnifying colonoscopy, early colorectal cancer, and flat adenomas. In: Waye JD, Rex DK, Williams CB, eds. *Colonoscopy: Principles and practice*. Malden, Oxford, Carlton: Blackwell, 2003:478-86.
19. Fujii T, Hasegawa RT, Saitoh Y, et al. Chromoscopy during colonoscopy. *Endoscopy*. 2001;33:1036-41.
20. Japanese Research Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum and anus. *Jpn J Surg* 1983;13:557-73.
21. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. *Gut* 2000;47:251-5.
22. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: A Japanese collaborative study. *J Gastroenterol* 2004;39:534-43.
23. Haggitt RC, Glotzbach RE, Soffer EE, et al. Prognostic factors in colorectal carcinomas arising in adenomas: Implications for lesions removed by endoscopic polypectomy. *Gastroenterology* 1985;89:328-36.
24. Kato S, Fujii T, Koba I, et al. Assessment of colorectal lesions using magnifying colonoscopy and mucosal dye-spraying: Can significant lesions be distinguished? *Endoscopy* 2001;33:306-10.
25. Bianco MA, Rotondano G, Marmo R, et al. Predictive value of magnification chromoendoscopy for diagnosing invasive neoplasia in nonpolypoid colorectal lesions and stratifying patients for endoscopic resection or surgery. *Endoscopy* 2006;38:470-6.
26. Ohta A, Tomimaga K, Sakai Y. Efficacy of magnifying colonoscopy for the diagnosis of colorectal neoplasia: Comparison with histopathological findings. *Digestive Endoscopy* 2004;16:308-14.
27. Saitoh Y, Obara T, Einami K, et al. Efficacy of high-frequency ultrasound probes for the preoperative staging of invasion depth in flat and depressed colorectal tumors. *Gastrointest Endosc* 1996;44:34-9.
28. Tsuruta O, Kawano H, Fujita M, et al. Usefulness of the high-frequency ultrasound probe in pretherapeutic staging of superficial-type colorectal tumors. *Int J Oncol* 1998;13:677-84.
29. Matsumoto T, Hizawa K, Esaki M, et al. Comparison of EUS and magnifying colonoscopy for assessment of small colorectal cancers. *Gastrointest Endosc* 2002;56:354-60.
30. Hurlstone DP, Brown S, Cross SS, et al. High magnification chromoscopic colonoscopy or high frequency 20 MHz mini probe endoscopic ultrasound staging for early colorectal neoplasia: A comparative prospective analysis. *Gut* 2005;54:1585-9.
31. Fu KI, Kato S, Sano Y, et al. Staging of early colorectal cancers: magnifying colonoscopy versus endoscopic ultrasonography for estimation of depth of invasion. *Dig Dis Sci* 2008;53:1886-92.
32. Uno Y, Munakata A. The non-lifting sign of invasive colon cancer. *Gastrointest Endosc* 1994;40:485-9.
33. Kobayashi N, Saito Y, Sano Y, et al. Determining the treatment strategy for colorectal neoplastic lesions: Endoscopic assessment or the non-lifting sign for diagnosing invasion depth? *Endoscopy* 2007;39:701-5.

CONFLICT OF INTEREST

This is not a collaborative study. Thus, this study being an absolutely independent investigation, there is neither financial support nor interest from any companies.

Nonpolypoid neoplastic lesions of the colorectal mucosa

Shin ei Kudo, MD, René Lambert, MD, FRCP, John I. Allen, MD, Hiroaki Fujii, MD, Takahiro Fujii, MD, Hiroshi Kashida, MD, Takahisa Matsuda, MD, Masaki Mori, MD, PhD, FACS, Hiroshi Saito, MD, Takakazu Shimoda, MD, Shinji Tanaka, MD, Hidenobu Watanabe, MD, Joseph J. Sung, MD, Andrew D. Feld, MD, John M. Inadomi, MD, Michael J. O'Brien, MD, David A. Lieberman, MD, David F. Ransohoff, MD, Roy M. Soetikno, MD, George Triadafilopoulos, MD, DSc, Ann Zauber, PhD, Claudio Rolim Teixeira, MD, Jean François Rey, MD, Edgar Jaramillo, MD, Carlos A. Rubio, MD, PhD, Andre Van Gossom, MD, Michael Jung, MD, Michael Vieth, MD, Jeremy R. Jass, MD, Paul D. Hurlstone, MD, FRCP

Japan, China, USA, Brazil, France, Belgium, Sweden, Germany, UK

INTRODUCTION

The progress in our understanding of early events in the development of colonic neoplasia is the result of 2 advances: (1) improved characterization of lesions detected at endoscopy and (2) new knowledge about the molecular biology of nonpolypoid lesions. Improved characterization of neoplastic lesions has been achieved through the addition of chromoscopy¹⁻⁵ and high-resolution endoscopy with magnification and image processing.⁶⁻⁹ New molecular knowledge about both sessile serrated lesions and flat adenomas has altered our understanding of the histogenesis of nonpolypoid lesions and their endoscopic management. A multidisciplinary workshop held in February 2008 in Kyoto, Japan, explored new aspects of our knowledge. This text summarizes the debate and ultimately the consensus among experts in endoscopy, pathology, and molecular biology of the colon.

In 1975, Muto et al¹⁰ described the histologic transition from a precursor adenomatous polyp to a confirmed colorectal cancer. Previous opinion, that colorectal cancer develops through a single pathway, has now been challenged, and it is clear that colorectal cancer can develop through multiple pathways, as reviewed by Jass¹¹ and Jass et al.¹² The morphology of premalignant colonic lesions depends on the direction of proliferating cell growth. Essentially, 3 types of lesions are now recognized: polypoid, nonpolypoid, and depressed. Polypoid lesions grow above the surface of the mucosa, rather than below, and the volume of the polypoid component appears to correlate with the histologic stage, as shown in the large series issued from endoscopy and pathology units in Japan and listed in the Paris classification.^{13,14} Nonpolypoid lesions may grow flat or slightly elevated and, even-

tually, may grow and progress to polypoid lesions or to laterally spreading tumors. Depressed lesions deserve special attention because of the difficulty in their detection, the need for special techniques (mucosectomy) to remove them by endoscopy, and a recognized increased risk of rapid progression to cancer, independent of size, as shown in endoscopy and pathology units in Japan.^{13,14} Nonpolypoid, depressed lesions progress in depth rather than above the surface of the mucosa, and submucosal invasion is frequent, even for small lesions (Figs. 1 and 2).

Sporadic colorectal neoplasia results from the disruption of normal cellular growth and senescence at a molecular level. In 1990, Fearon and Vogelstein¹⁵ demonstrated that a mutation within the adenomatous polyposis coli (APC) tumor-suppressor gene initiated one of the major neoplasia pathways. This mutation was linked to chromosomal instability (CIN) and loss of heterozygosity (LOH). Subtle molecular differences cause alternative growth patterns, such as polypoid or nonpolypoid (including the flat adenoma and flat cancer), and they, subsequently, will be discussed.

In the last decade, the serrated pathway has been described as an alternative pathway to colorectal cancer. Serrated lesions refer both to hyperplastic (HP) (nonneoplastic) lesions, often called HP polyps, and sessile serrated lesions, often called sessile serrated adenomas (SSAs); the latter are considered the precursor for microsatellite instable (MIS) cancers. An early event in the growth of sessile-serrated lesions is an inactivating mutation within the BRAF gene encoding the B-RAF protein kinase. Progression from nondysplastic sessile-serrated lesions to neoplasia requires epigenetic silencing of hMLH1, one of the mismatch repair (MMR) genes. Inactivating methylation of hMLH1 disrupts the MMR cascade, which results in the accumulation of mutations in a variety of genes, some of which lead to neoplasia and MIS cancers.

ENDOSCOPIC CLASSIFICATION OF POLYPOID AND NONPOLYPOID SUPERFICIAL LESIONS

The morphology of superficial neoplastic or nonneoplastic lesions in the colorectal mucosa is protruding (polypoid) or flat (nonpolypoid). Premalignant and malignant

Abbreviations: ACF, aberrant crypt foci; APC, adenomatous polyposis coli; CIMP, CpG-island methylation phenotype; CIN, chromosomal instability; FAP, familial adenomatous polyposis; HGIN, high-grade intraepithelial neoplasia; HNPCC, hereditary nonpolyposis colon cancer; HP, hyperplastic; LOH, loss of heterozygosity; LST, laterally spreading type; m, mucosa; MIS, microsatellite instable; MMR, mismatch repair; MSS, microsatellite stable; NBI, narrow-band imaging; sm, submucosa; SSA, sessile serrated adenoma; TSA, traditional serrated adenoma.

Copyright © 2008 by the American Society for Gastrointestinal Endoscopy
0016-5107/\$34.00
doi:10.1016/j.gie.2008.07.052




Figure 1. Models of tumor growth during the development of colorectal neoplasia: Progression occurs in 4 distinct models: (1) as a polypoid protruding lesion in an upward direction, (2) as a nonpolypoid depressed lesion, which progresses in a downward direction in depth, (3) as a nonpolypoid lesion, which remains either flat or slightly elevated, and (4) as a LST lesion.




Figure 2. Subtypes of nonpolypoid neoplastic lesions. The nondepressed types, elevated or completely flat (0-I Ia, 0-I Ib), are stable or progress to polypoid or LST lesions. The depressed type (0-I Ic) can progress to a mixed morphology, 0-I Ic + 0-I Ia and then 0-I Ia + 0-I Ic. When the tumor increases in depth, the surface of the depression may be elevated, even in small lesions.

neoplastic lesions of the digestive mucosa are called superficial when their appearance at endoscopy suggests that their depth is limited to the mucosa (m) or submucosa (sm). Nonpolypoid (flat) small neoplastic lesions are frequent in human beings, and some of them show a fast progression to cancer, in spite of maintaining a small size. In the absence of adenomatous remnants, these lesions appear to be “de novo” cancer. The nonpolypoid model of neoplastic growth is confirmed in animal studies, because it can occur spontaneously in baboons¹⁶ or after administration of the carcinogen dimethyl hydrazine in rats.^{17,18} Nonprotruding carcinomas may be found

TABLE 1. Morphologic classification of type 0 lesions with superficial appearance at colonoscopy (Paris-Japanese classification)

Polypoid type*	Pedunculated (0-Ip)
	Sessile (0-Is)
	Mixed (0-Isp)
Nonpolypoid type	Slightly elevated (0-I Ia)
	Completely flat (0-I Ib)
	Slightly depressed (0-I Ic)
Mixed types	Elevated and depressed (0-I Ia + Ic)
	Depressed and elevated (0-I Ic + I Ia)
	Sessile and depressed (0-Is + Ic)

*Polypoid lesions are elevated more than 2.5 mm above the surrounding mucosa. Nonpolypoid lesions are flat, elevated less than 2.5 mm, or are depressed less than 2.5 mm. Slightly elevated lesions should not be mistaken for sessile or flat lesions.

throughout the colon, whereas protruding carcinomas are more prevalent in the distal portion of the colon.

The endoscopic morphology of superficial neoplastic lesions was described by Japanese endoscopists and was classified into various subtypes: category 0 refers to superficial invasion, whereas categories I to V correspond to advanced cancer with invasion deeper than the submucosa. The Paris classification^{13,14} is similar to the Japanese classification, as illustrated in Table 1. Polypoid lesions may be pedunculated (0-Ip), sessile (0-Is), or with a mixed pattern (0-Isp). Nonpolypoid lesions are either slightly elevated, termed 0-I Ia (elevation <2.5 mm above the level of the mucosa), completely flat (0-I Ib), or slightly depressed (0-I Ic). Completely flat and depressed lesions are rare in the colonic mucosa, whereas slightly elevated lesions are more prevalent. Excavated (0-I II) superficial lesions are extremely rare in the colon. Slightly depressed (0-I Ic) lesions are especially important to recognize, because they often harbor invasive cancer, despite their small diameter. The morphology of superficial neoplastic lesions is shown in the Image Atlas.

In the colon and the rectum, the distinction between polypoid and nonpolypoid lesions and the specific character of depressed lesions was extensively explored in Akita and in Yokohama by Kudo.¹⁹⁻²⁵ An accurate analysis is hampered by multiple factors that can be controlled if the endoscopist and the pathologist describe the gross morphology of endoscopic or surgically resected specimens in the same subtypes of the Paris classification.^{13,14}

First, nonpolypoid lesions are less conspicuous than polypoid lesions, so they are often missed, especially by those endoscopists who are not trained in techniques used in the East. Recent series with high-definition video endoscopes may provide more reliable estimations. Second, nonpolypoid, slightly elevated (0-I Ia) lesions are




Figure 3. LST lesions. Models of granular and nongranular LST of neoplastic lesions, with the corresponding classification according to the categories of the Paris classification.

often misclassified as sessile (0-Is). For example, 1505 superficial neoplastic lesions found in the National Polyp Study²⁶ and previously classified as polypoid were reviewed in light of the new terminology. After revision, there were 802 polypoid pedunculated lesions, 229 polypoid sessile lesions, and 474 nonpolypoid lesions (31.4%) called flat. The proportion of severe neoplasia in this group is very low (1.3%), but no distinction was made among elevated, completely flat, or depressed subtypes. Third, all subtypes of nonpolypoid lesions are often called "flat lesions," without distinguishing the important, but rare, depressed lesions, which frequently are invasive cancers. Fourth, nonpolypoid neoplastic lesions may show a mixed pattern of both a polypoid sessile and a nonpolypoid morphology in distinct sectors. Laterally spreading type (LST) lesions, which were described by Kudo²⁴ in relation to their transversal mode of growth, should be further distinguished based on their granular or nongranular, homogenous or nonhomogenous appearance. Their relationship to the categories of the Paris classification is often a source of confusion. Some LST lesions can be classified as nonpolypoid, in the subtypes 0-IIa or 0-IIa + IIc. Other LST lesions associate with a polypoid (0-Is) or a nonpolypoid pattern. Some nongranular subtypes of LST are called pseudodepressed, to underline the distinction from simple depressed 0-IIc lesions (Fig. 3, Table 2).

HISTOLOGIC CLASSIFICATION OF ADENOMAS AND CARCINOMAS

Adenoma

An adenoma is a premalignant lesion that shows intraepithelial neoplasia without invasion of the mucosal stroma and is always associated with cytologic neoplasia. The identification of an adenoma is based on 2 types of alterations: structural and cytologic. The structural or architectural features include simple-to-complex crowding of glands, lateral expansion, and irregularity. According to their architecture, adenomas are classified as tubular, tubulovillous, or villous types: at least 20% of the estimated volume of the lesion should be villous to classify an adenoma as tubulovillous

TABLE 2. Subtypes of LST lesions: morphologic classification of LST lesions and their correspondence in the Paris-Japanese classification*

Subtypes of LST	Classification in type 0
LST granular	
Homogenous type	0-IIa
Nodular mixed type	0-IIa, 0-Is + IIa, 0-IIa + Is
LST nongranular	
Elevated type	0-IIa
Pseudodepressed type	0-IIa + IIc, 0-IIc + IIa

*The term "laterally spreading type (LST)" refers to the lateral growth of lesions at least 10 mm in diameter; this is in opposition to traditional polypoid (upward growth) or flat and depressed lesions (downward growth).

and 80% villous to be defined as a villous adenoma; all other adenomas are classified as tubular. In the Vienna classification, an adenoma with marked structural alterations is classified as high-grade intraepithelial neoplasia (HGIN)^{27,28} (Table 3). Cytologic features of cell atypia consist of 2 to 5 rows of palisading or enlarged nuclei, with a dispersed chromatin pattern and prominent nucleoli. High-grade cytologic abnormalities, with a loss of polarity, stratification, and atypical mitotic figures, usually coexist with architectural alterations and may be difficult to distinguish from intramucosal carcinoma.

The clinical relevance of the terminology "advanced adenoma," often used in endoscopic series, is linked to a significant risk of progression to cancer and demands a prompt treatment decision. Advanced adenomas are either large lesions, at least 10 mm in diameter (endoscopic criteria), or adenomas, with a villous architecture, or HGIN (histologic criteria).

Adenocarcinoma

An intramucosal adenocarcinoma is characterized by the invasion of neoplastic cells in the stroma of the tunica (lamina) propria. Extension to the submucosa across the muscularis mucosae characterizes submucosal adenocarcinoma. The term "early" colorectal cancer includes both intramucosal and submucosal adenocarcinomas. Extension beyond the submucosa defines "advanced" cancer. If a carcinoma is contained completely within the mucosa, the risk of lymph-node and vascular invasion is nil; as a rule, endoscopic resection is a legitimate treatment for those lesions. If there is submucosal invasion, then extension to endothelium-lined vascular spaces is regarded as a significant risk for lymph-node invasion or distant metastases. Risk increases in proportion to the depth and width of invasion in the submucosa. When invasion is slight, endoscopic treatment may be legitimate; when invasion is extensive, surgery is required. The boundary between endoscopic or

TABLE 3. Histopathologic classification of superficial neoplastic lesions of the colorectal mucosa

Pragmatic classification*		Correspondence to Vienna classification	Clinical relevance
Normal mucosa or inflammation hyperplasia (metaplasia)	No neoplasia	Negative for neoplasia Indefinite for neoplasia	Endoscopic treatment
Low-grade neoplasia	Noninvasive (low-grade and high-grade adenoma)	Noninvasive low-grade IEN Noninvasive high-grade IEN	Endoscopic or surgical treatment
	Invasive† (low-grade carcinoma; no risk factors)	Mucosal carcinoma or submucosal carcinoma	
High-grade neoplasia	Invasive (high-grade carcinoma with risk factors)	Mucosal carcinoma or submucosal carcinoma	

IEN, Intraepithelial neoplasia.

*This pragmatic classification applies to the adenoma-adenocarcinoma sequence and to neoplasia in serrated lesions. Risk factors for the progression of cancer include one of the following: vessel permeation, incomplete polypectomy and/or resection, poor differentiation, marked budding of tumor cells, or infiltration equal or deeper than the lower third of the submucosal layer. Risk factors are absent in low-grade invasive cancer and present in high-grade invasive cancer. Low-grade intramucosal neoplasia is treated with legitimacy by endoscopy. High-grade intramucosal neoplasia, identified on cytologic characters, may require a more radical treatment.

†(1) Invasive: in stroma of mucosa or submucosa; (2) intraepithelial neoplasia (IEN); (3) signet-ring-cell carcinoma is equivalent to high grade neoplasia.

surgical treatment can be estimated before treatment, but confirmation of its legitimacy is retrospective when the pathologist examines the complete operative specimen.

Pathologists have proposed various methods of estimation of the degree of invasion in the submucosa in superficial cancer. Pedunculated lesions were graded by Haggitt et al,²⁹ and sessile lesions were graded by Kudo²¹ and Kudo et al²² and Kikuchi et al³⁰; the latter system can also be adapted for nonpolypoid lesions. For example, the risk of lymph-node metastases is 2%, 8%, and 23% for Kikuchi levels sm1, sm2, and sm3 (the upper, middle, and lower level of the submucosa), respectively. The ability to estimate the depth of submucosal invasion in resected nonpolypoid lesions has become more precise with the development of strip mucosectomy and submucosal dissection.

For most endoscopic resection specimens, dividing the submucosa into 3 parts is not applicable, because the limit of the muscularis is not included. A precise assessment of the depth of invasion requires a micrometric measurement from the lower part of the muscularis mucosae to the limit of invasion. This method has been adopted in Japan, where 1000 μ is the lower limit for which adequate endoscopic treatment can be assumed. In daily practice, the pathologist can estimate the depth of invasion in the submucosa as sm1 if less than half of the segment of submucosa is included within the specimen; as sm2, if the invasion is beyond this limit; and as sm3, if the cancer is positive at the cut margin. One can also estimate invasion in depth in 3 levels (sm1, sm2, sm3) and in transversal extension just below the muscularis mucosae in 3 levels (sm1a, sm1b, sm1c). This double measurement is adopted in the analysis of the neoplastic lesions that are resected at

the Yokohama endoscopy unit in Japan. A slight invasion of the submucosa corresponds to sm1a or sm1b. An extensive invasion corresponds to transverse extension sm1c or to levels sm2 and sm3 in depth.

Flat adenocarcinoma and de novo cancer

For more than 2 decades, Japanese endoscopists have been giving special attention to nonpolypoid flat or depressed adenomas^{31,32} and to flat minute adenocarcinomas³³⁻³⁵ similar to minute gastric cancers.³⁶ Particular attention was given by Kudo et al¹⁹⁻²¹ and Kudo and Muto²⁵ to the specific differences between flat and depressed lesions in the colorectal mucosa. A cancer is called de novo when it is assumed to develop without an adenomatous precursor.³⁷ In spite of being small, and even inconspicuous, such lesions are evolutive and often should be treated by surgery.

The quest for adenomatous remnants in colorectal cancer

Various studies, based on analysis of operative specimens, suggest that a substantial proportion of colorectal adenocarcinomas develop de novo³⁸⁻⁴⁸; the figures range from 20% to 90%, averaging around 40%. In Japan, the proportion of adenoma remnants was analyzed in relation to morphology. In specimens of early cancer, Shimoda et al³⁷ showed that the polypoid morphology was frequent (82%) and included adenomatous remnants in 91% of cases (133 of 146); nonpolypoid morphology was less frequent and never included adenoma remnants (0 of 32). The average diameter of nonpolypoid early cancer was smaller, and invasion in the submucosa was more frequent. In contrast,

TABLE 4. Grade of superficial colorectal cancer in Japan*

	Carcinoma with low or high malignancy	
	Low grade	High grade
Cytologic parameters		
Cellular atypia	Low proportion	High proportion
K67 labeling cells	Low index	High index
Depth of invasion		
Intramucosal	Most cases	Few cases
Submucosal	Few cases	Most cases
Morphology		
Polypoid	Most cases	Few cases
Depressed	Few cases	Most cases

*Well-differentiated intramucosal or submucosal cancer is classified on cytologic criteria as low-grade or high-grade malignancy. The majority of submucosal cancer is "high grade." The majority (80%-85%) of intramucosal cancer is "low grade." Low-grade intramucosal cancer is also called high-grade adenoma. The term "cancer" is maintained for high-grade intramucosal neoplasia and for submucosal lesions.

Legitimacy of the terminology *de novo* cancer

In the colorectal mucosa, a *de novo* cancer is assumed to develop without an adenomatous precursor.³⁷ This assumption relies primarily on the absence of adenomatous tissue in small and flat malignant lesions, but, it is also possible that malignant transformation has obliterated any remnant of a flat or depressed small adenoma. The hypothesis of the direct malignant growth is supported by the very low occurrence of adenoma remnants in flat early cancer and by the shift in the proportions of the polypoid and nonpolypoid morphology in early versus advanced cancers.

Regardless, a *de novo* cancer is characterized by a nonpolypoid growth pattern, a smaller size, and a more frequent invasion into the submucosa.⁴⁰ Flat adenocarcinomas are characterized by specific molecular events that begin in their early stage. The *de novo* colorectal cancers represent a small fraction of early cancers but will account for a higher proportion of advanced cancers, with most estimates being in the range of 40%. By using a cohort of patients distributed in 3 groups, that is, negative colonoscopy, polyps, and cancer, Chen et al³⁹ estimated the dwelling time to cancer in the classical adenoma-carcinoma sequence and in the *de novo* sequence by a Markov analysis. Their analysis suggests that at least 30% of colorectal cancers arise from the *de novo* sequence.

the same investigators showed a high (78.2%) proportion of nonpolypoid cancer in 853 operative specimens of advanced cancer, and they estimated that around 80% of colorectal cancers arise as *de novo*. Kuramoto and Oohara,⁴³ in 1995, observed the absence of adenoma remnants in 89.7% of flat early cancers (87 of 97) and in only 16.6% of polypoid early cancers (23 of 138). Submucosal invasion occurred in 53.6% of flat early cancers and in 13.8% of polypoid early cancers. Kaneko et al⁴⁷ analyzed the morphology of 107 specimens and confirmed that tumors with a nonpolypoid morphology were smaller (33 vs 55 mm in diameter), with a higher proportion of vascular invasion (95% vs 74%). In Europe, Eide⁴⁴ found adenoma remnants in 53% of polypoid cancers and in only 12% of nonpolypoid cancers. Bedenne et al³⁸ estimated that 40% of cancer arose *de novo* from the analysis of 1630 operative specimens; adenoma remnants were present in 25.8% of protruding tumors and in only 0.5% of ulceroinfiltrative tumors (0.5%). George et al⁴⁵ estimated the proportion of *de novo* cancers at 48% from an analysis of 186 advanced cancers; adenoma remnants were found in 52% of polypoid and in only 2% of nonpolypoid cancers.

Other histopathologic studies based on endoscopic features of the flat, *de novo*, early colorectal cancers led to a similar conclusions. Goto⁴⁶ classified 83 cases of early cancers in 2 types: polypoid (84% of cases) and flat, *de novo* cancers, without adenoma remnants (22.9% of cases). Kuramoto and Oohara⁴² analyzed the morphology of 37 flat early cancers and found frequent invasion in the submucosa, in spite of the small size of the lesions.

Low-grade and high-grade adenocarcinoma

The distinction between low-grade and high-grade adenocarcinoma currently used in Japan applies only to well-differentiated tumors, and the grade is established on cytologic rather than on structural criteria (Table 4), as shown by Ajioka et al⁵⁵ and Maeo et al.⁴⁸ Low-grade and well-differentiated adenocarcinomas show hyperchromatic and elongated nuclei, in basal arrangement, limited to two thirds of the epithelium and are less evolutive and less invasive than high-grade tumors. High-grade and well-differentiated adenocarcinomas show an increased crowding of round, large, and irregular nuclei, migrating up to the apical pole of epithelial cells and an increased mitotic index, and tend to be more invasive, with possible lymph-node invasion, even when intramucosal. With immunohistochemistry, high-grade tumors show a high index of Ki-67-labeled cells or, alternatively, an increased expression of proliferating cell nuclear antigen,⁴⁸ a diffuse expression of beta-catenin, an adhesion protein that binds cadherin, and a higher expression of dysadherin, a cell-membrane glycoprotein. A positive immune-labeling of CD-10 may indicate a higher risk for liver metastasis.⁴⁹

Immunostaining with dysadherin and beta-catenin was explored by Shimoda (unpublished data, 2008) at the National Cancer Center, Tokyo, in 128 superficial neoplastic colorectal lesions (adenoma or carcinoma), classified into the high-grade or low-grade types. Dysadherin expression was lower in adenoma (32%) than in cancer, in which the rates were 58% and 83% for low-grade and




Figure 4. Representation of serrated lesions: (1) HP lesion (notched crypt lumen, cell multiplication, and growth in the “bottom-up” direction), (2) another HP lesion (goblet-rich type with normal cell nuclei), (3) Sessile serrated lesion (a crypt with a notched lumen, discontinuous proliferation zones, horizontal spread of basal crypt with mature goblet cells), often called a sessile serrated adenoma, and (4) Another sessile serrated lesion: increased mucus, elongated nuclei (by J. R. Jass).

high-grade intramucosal cancer, respectively, and were 50% and 74% for submucosal cancer, respectively. In addition, the diffuse expression of beta-catenin was absent in adenomas and was frequent in cancer, in which the proportions were 27% and 72% for low-grade and high-grade intramucosal cancer, respectively, and 50% and 79% for low-grade and high-grade submucosal cancer, respectively. The majority of intramucosal cancers are “low grade,” whereas most submucosal cancers are “high grade.” The distinction between low-grade and high-grade differentiated adenocarcinoma is relevant to the legitimacy of a local excision. Low-grade intramucosal or submucosal cancer is safely treated by endoscopic resection. High-grade cancer (even intramucosal) deserves special management, and surgery may offer a legitimate alternative to endoscopic treatment.

Vienna classification

Some discrepancies between Western and Eastern pathologists deserve emphasis: (1) low-grade or high-grade structural alterations of the epithelium, without invasion of the stroma, have been called dysplasia; the tendency is now to substitute this term with that of “noninvasive intraepithelial neoplasia”; (2) The World Health Organization definition of colonic adenocarcinoma (in contrast to the Japanese experience) requires a confirmation of invasion into the submucosa; intramucosal carcinoma is then classified as HGIN and will not be included in cancer reg-




Figure 5. Representation of serrated and adenomatous lesions: (1) adenoma (cell multiplication and growth in the direction of lateral and top-down growth [arrows]), (2) traditional adenoma (elongated and packed nuclei with cellular atypia), and (3) TSA (elongated nuclei, cellular atypia, vertical direction of basal crypts with intraepithelial microacinar insets) (by J. R. Jass).

istries. The Vienna classification, and its revised edition,^{27,28} achieves a relative consensus between Western and Eastern experts and classifies the severity of epithelial alterations in the mucosa, as well as the extension to the submucosa, as shown in Table 3: (1) negative for neoplasia, (2) intramucosal neoplasia with noninvasive low-grade intraepithelial neoplasia and HGIN and with invasive HGIN, and (3) submucosal adenocarcinoma.

The pragmatic classification adopted in this article is relevant to the treatment decision planned (no intervention, or endoscopic or surgical resection) and includes 2 modifications of the Vienna classification: (1) the categories “indefinite” for noninvasive or invasive neoplasia were withdrawn and (2) the distinction between low-grade or high-grade carcinoma was included. In this situation, low-grade intramucosal neoplasia includes noninvasive (low grade and high grade) intraepithelial neoplasia and low-grade carcinoma. High-grade intramucosal neoplasia corresponds to a high-grade intramucosal carcinoma.

HISTOLOGIC CLASSIFICATION OF SERRATED LESIONS

The term “serrated” refers to the histologic appearance of a variety of polyps, the edge of which has a wavy or

TABLE 5. Classification of serrated colorectal lesions*

Serrated lesions: upper crypts (serration), basal crypts (normal proliferation), small basal nuclei	Microvesicular type; predominance of microvesicular cells	Nonneoplastic†
	Goblet-cell-rich type; predominance of goblet cells	
	Mucin-poor type; reduction in mucin in cells	
Serrated lesions: upper crypts (serration), basal crypts (abnormal proliferation), increased mucus	Sessile serrated lesion (often called adenoma); basal crypts; horizontal growth; architectural distortion; elongated nuclei; more mucus; atypia (structural, not cytologic)	
	TSA; basal crypts; vertical growth; neoplasia (structural and cytologic)	Neoplastic
Mixed polyp: mixed parts of HP lesion, classical adenoma	HP and classical adenoma	
	HP and serrated adenoma	

*The term serrated refers to the notched irregular diameter of the crypt lumen. These lesions are nonneoplastic (HP lesions) or neoplastic (serrated adenomas) or a composite with juxtaposition of HP and adenomatous sectors. Sessile serrated lesions are not classified as neoplastic, because there is no cellular atypia in the serrated zone with abnormal architecture.

†Nonneoplastic lesions can theoretically harbor foci of neoplasia; they are considered as neoplasia developed on a nonneoplastic lesion or they belong to the group of mixed polyps.

serrated contour. The specific architectural feature deserving the term "serrated" is the irregular and enlarged upper part of the crypts, which are notched like a saw with teeth pointing toward the center of the lumen; the serration index describes the severity of the architectural defect. There is some confusion in the classification of serrated lesions as neoplastic or nonneoplastic, based on whether there is a normal or abnormal proliferation within the crypts. So-called HP polyps have a normal proliferative compartment and very rarely progress to neoplasia. In contrast, traditional serrated adenomas (TSAs) are neoplastic. Sessile serrated lesions appear to be a precursor to cancer with MIS, when they show abnormal proliferation within the crypts. Serrated lesions display a morphology that is similar to that of neoplasia arising from the adenoma-adenocarcinoma sequence⁵⁰⁻⁷⁴; however, the surface pattern explored with magnification shows specific characters with enlarged and stellar crypt openings. There is some confusion in their morphologic classification (Figs. 4 and 5, Table 5) as polypoid or nonpolypoid. The terminologic HP polyp, which suggests polypoid morphology, is legitimate for unequivocally protruding lesions, which belong to categories 0-Ip or 0-Isp. However, most of the frequently small and <10-mm HP lesions are nonpolypoid and should be classified in the category 0-IIa. Large, sessile serrated lesions located in the right side of the colon adopt a transverse mode of growth, which results in mixed polypoid and nonpolypoid patterns: 0-IIa + IIc or 0-Is + IIa or 0-IIa + IIc, which are often misclassified as LST lesions.

HP polyps

HP polyps are metaplastic, not neoplastic, lesions. They are composed of elongated crypts, with a serrated architecture in the upper half of the crypts, that results in irregular dilatation of the notched lumen.^{50,52,54} There is some

regular cell proliferation in the basal, nonserrated part of the crypts. Nuclei are small, regular, and basally orientated; there is no stratification in the upper half of the crypts, and both architectural and cytologic features of neoplasia are absent. Three distinct types of cytoplasmic differentiation were described in HP lesions: (1) a microvesicular type, (2) a goblet-cell-rich type, and (3) a mucin-poor type. Practically, it might be very difficult to distinguish these subtypes. The microvesicular type HP lesion may be the precursor of the sessile serrated lesion, whereas the goblet-cell-rich type HP lesion may be the precursor of the TSA. The morphology of HP lesions was described in Japan in a large series ($n = 3060$), in which the majority of lesions were small and located in the distal portion of the colon.⁴⁸ As a rule, the risk of progression to neoplasia is negligible for most small lesions located in the distal portion of the colon and rectum, and they may be left without treatment. However, HP lesions larger than 10 mm and those located in the proximal portion of the colon should be resected.

With HP polyposis, the larger and sessile lesions show a high serration index with laterally branching crypts and abnormal cell maturation (mitoses, nuclear changes). In this condition, more than 30 small, or more than 5 large lesions, larger than 1 cm are present in the colon. The large or giant lesions have a sessile morphology and are located in the proximal portion of the colon. HP polyposis is associated with an increased risk of colorectal cancer, evaluated in a series at 54%.⁵⁶ Patients with HP polyposis are at high risk for colorectal cancer developed in the proximal portion of the colon.

TSAs

TSAs show neoplastic crypts with a serrated architecture.⁵⁷⁻⁷⁰ They differ from HP lesions by the complex serrated architecture of the basal part of the crypts, with

TABLE 6. Categories of the pit pattern at the surface of the colonic mucosa*

Histology	Pit pattern†		Treatment selection
Nonneoplastic	Normal mucosa (normal round crypts, regular)	I	No treatment
	HP lesion (enlarged stellar crypts, regular)	II	
Neoplastic, adenomatous	Neoplastic lesion (elongated, sinuous crests)	IIIL	Endoscopic resection
	Neoplastic lesion (narrowed round pits, irregular)	IIIS	
	Neoplastic lesion (branched or gyrus-like crests)	IV	
Neoplastic, cancer	Malignant lesion (irregular surface)‡	VI	Endoscopic resection
	Malignant lesion (amorphous surface)‡	VN	Surgery

*Exploration conducted in magnification with chromoscopy or NBI.

†The 7 categories observed are classified in reference to prediction of histology and treatment decision.

‡Pit pattern V is divided in 2 categories: VI with an irregular surface and VN, or nonstructural, with an amorphous surface.

elongated nuclei and some stratification in 2 to 3 rows. A BRAF mutation is present in 75% of serrated adenomas.⁶⁹ These lesions should be treated in the same way as non-serrated adenomas.

Sessile serrated lesions

Sessile serrated lesions, often called SSAs, differ from traditional adenomas by their flat morphology.⁷¹⁻⁷³ There is a double ambiguity in their classification under this name. These lesions show no adenomatous changes and should be called "sessile serrated lesions." The term sessile is also confusing, because these lesions often show a nonpolypoid, slightly elevated (0-IIa) morphology rather than a sessile polypoid (0-Is) one.

The frequency of sessile serrated lesions is estimated at about 2% of all colon polyps. However, in a recent study of patients undergoing colonoscopy,⁷² the prevalence of sessile serrated lesions was higher (9%). These lesions are associated with the following characteristics: proximal location, female sex, and multiplicity. Architectural features of sessile serrated lesions include the following: (1) an increased serration index in the basal half of crypts, which are dilated, with crypt branching with horizontal growth, and form T-shaped and L-shaped glands just above the muscularis mucosae, (2) an asymmetrical expansion of the proliferation zone into the middle third of crypts, (3) an epithelium-to-stroma ratio often above 50%, (4) an abundant mucus production, with pools of mucin in the lumen of the crypts and on the surface of the mucosa, (5) the presence of slightly enlarged vesicular nuclei with nucleoli. The structural abnormalities that show a complex architecture are compatible with neoplasia, but the cytologic criteria of neoplasia are missing.

The distinction between sessile serrated lesions and serrated adenomas, therefore, mainly depends on cytologic criteria; in addition, Torlakovic et al⁷³ proposed another difference: the eosinophilic cytoplasm of sessile

serrated lesions. Although most sessile serrated lesions will never progress to neoplasia, some, particularly the large sessile serrated lesions in the proximal portion of the colon, progress rapidly to carcinoma⁷²; as a rule, those located in the proximal portion of the colon should be resected.

Mixed polyps

Mixed polyps contain distinct sectors that show the architecture of an HP lesion and/or that of a neoplastic serrated lesion.⁷⁴ The following mixed patterns have been acknowledged: HP and sessile serrated lesions, HP and TSA, TSA and classical adenoma, sessile serrated lesion and classical adenoma, and TSA and sessile serrated lesion. Mixed polyps should be treated in the same way as TSAs and nonserrated neoplastic lesions.

CLASSIFICATION OF THE SURFACE PATTERN OF NONPOLYPOID LESIONS ON MAGNIFYING ENDOSCOPY

Magnification of the endoscopic image at a power $\times 80$ or more combines optical and electronic technologies and displays the microarchitecture (pits and crests) of the mucosa, which allows classification with clinical relevance for the "pit pattern." Magnification can be coupled with image processing. In the narrow-band imaging (NBI) technique (Olympus Medical Systems Corp, Tokyo, Japan), a special set of filters is interposed on the optical path, and the incident photons are emitted in 2 narrow bands of wavelengths (blue and red). The selective reflection of the NBI light by the superficial layers of the mucosa improves the definition of the surface, and the vessels are highly contrasted in dark brown. Analysis of the disorganized "vascular pattern" in the neoplastic mucosa is now a major application of the NBI technique.

TABLE 7. Categories of the pit pattern of superficial neoplastic lesions: exploration conducted in magnification with chromoscopy or NBI

	Total no. lesions	Pit pattern*				
		III _L	III _S	IV	VI _{ij}	VN _†
Polypoid (0-Ip, Ips, Is)	14,084 (61.1%)	10,208	17	3236	511	112
Nonpolypoid (not depressed, 0-IIa, IIb)	8405 (36.4%)	7453	78	551	245	78
Nonpolypoid (depressed, 0-IIc)‡	559 (2.4%)	70	257	1	53	178
Total	23,048	17,731	352	3788	809	368

*Categories of pit patterns in relation to the morphology of 23,048 lesions in the series at the Akita and Yokohama Northern Hospitals during the period April 1985 through July 2007.

†Lesions with a depressed pattern account for 2.4% of all superficial neoplastic lesions (n = 23,048) and for 31.9% of pit pattern types III_S + VI + VN.

‡Pit pattern V is divided in 2 categories: VI, with an irregular surface, and VN, or nonstructural, with an amorphous surface.

TABLE 8. Categories of the vascular pattern at the surface of the colonic mucosa: exploration conducted in magnification with NBI

Histology		Vascular pattern*	Selection of treatment
Nonneoplastic	Normal	Well-delineated capillaries surrounding pits opening	No treatment
	Faint	Poor visibility of capillaries around enlarged pits	No treatment
Neoplastic (tubular, villous adenoma)	Network	Vessels organized in a large and regular mesh	Endoscopic resection
	Dense	Enlarged vessels of regular size at top of elongated epithelial crests	Endoscopic resection
Cancer	Irregular	Enlarged vessels of irregular diameter and diverging directions	Endoscopic resection
	Sparse	Poor distribution of irregular vessels with diverging directions	Surgery

*The 6 categories are classified in reference to prediction of histology and treatment decision.

Classification of the pit pattern

The pit pattern, ie, the microarchitecture of pits, epithelial crests, or ridges, at the surface of the normal or altered colonic mucosa is observed in magnifying endoscopy,⁷⁵⁻⁷⁷ with the help of chromoscopy by using a 0.2% indigo carmine solution or other dyes. Alternatively, the contrast of the surface is explored without chromoscopy when NBI is coupled with magnification. The progressive alterations of the pit pattern in neoplastic lesions have been confirmed by many investigators since the initial Kudo's classification of the abnormal patterns: (1) in the normal mucosa, the luminal opening of the crypts are round, regular, and narrow, (2) in the non-neoplastic HP lesions, the crypt lumen is large and stellar shaped, (3) in neoplastic lesions, epithelial crests and ridges substitute for this regular honeycomb distribution, and (4) carcinoma is suggested when the surface is irregular, without epithelial crests, or completely amorphous and nonstructural. A grading of the progression of neoplasia in relation to the pit pattern, classified in categories I to VN, has been proposed in Japan (Table 6), and compared with histology in a very large (> 23,000) series of superficial neoplastic lesions of the colorectal mu-

cosa (Table 7). The study confirms that depressed nonpolypoid lesions are more advanced than the other lesions, and the pit pattern type V occurs in 41% of them. The proportion of pit pattern V in nondepressed (nonpolypoid or polypoid) lesions is less than 5%. The clinical relevance of the pit pattern for the grading of neoplasia is still debated when 7 categories are used but is well accepted when a simpler classification in 3 categories is used: (1) nonneoplastic (I and II), (2) neoplastic low grade (III), or (3) neoplastic high grade (IV and V).

Classification of the vascular pattern

The vascular pattern at the surface of the digestive mucosa is observed in magnifying endoscopy and in transparency without chromoscopy; the contrast of the vessels is improved when NBI is coupled with magnification. There are still few descriptions of the vascular pattern in the colonic mucosa. For example, in the normal mucosa, well-delineated capillaries surround the opening of the crypts. The endoscopy unit of the Northern Yokohama Hospital analyzed the abnormal aspects according to the following criteria of the capillaries: degree of visibility, enlarged or

TABLE 9. Comparison of the vascular pattern of traditional and serrated adenomas: exploration conducted in magnification with NBI

Vascular pattern*	Adenoma		Total
	tubular or villous	Serrated adenoma	
Faint†	1	14	15
Network	446	8	454
Dense	119	12	131
Irregular	1	0	1
Sparse	0	0	0
Total	567	34	601

*The vascular pattern is analyzed at the surface of tubular or villous adenomas and of serrated adenomas in the series the Yokohama Northern Hospital during the period January 2006 through August 2007.

†Faint pattern that suggests an HP lesion is observed in 41% of serrated adenomas.

irregular diameter, or the absence of symmetry in the direction of capillaries. The abnormal aspects are classified in 5 groups: "faint," "network," "dense," "irregular," and "sparse." In the same endoscopy unit, the vascular pattern at the surface of superficial lesions of the colorectal mucosa was correlated to histology during the period January 2006 through September 2007 (S. Kudo, H. Kashida, unpublished data, 2008). A "faint" vascular pattern occurred in 37 of 41 HP lesions and in only 15 of 843 neoplastic lesions. The sensitivity and specificity of the "faint" pattern for HP polyps were 98.2% and 90.2%, respectively. A "nonfaint" vascular pattern, which regrouped all 4 other abnormal patterns, occurred in 823 of 843 neoplastic lesions and in only 4 of 41 HP lesions. The "nonfaint" patterns characterize neoplastic lesions. The classification of the vascular pattern helps in the distinction among non-neoplastic lesions, premalignant neoplastic lesions, and cancer (Table 8), and in the distinction between traditional adenomas and serrated adenomas (Table 9).

GENETIC FACTORS THAT CONTROL THE GROWTH OF TUMORS IN THE COLORECTAL MUCOSA

Considerable progress⁷⁸⁻⁹⁶ has occurred during the most recent years in the description of genetic events for the adenoma-carcinoma sequence, the HP serrated carcinoma sequence, hereditary cancer,⁹⁷⁻⁹⁹ and cancer in inflammatory bowel disease.¹⁰⁰⁻¹⁰⁴ A link has been established between the genetic events that control the development of the neoplastic lesions and their morphology (Tables 10 and 11). Colorectal carcinoma develops in 3 distinct genetic pathways: (1) CpG-island methylation phenotype (CIMP), which is classified as

high, low, or negative, will inactivate encoding regions of DNA by methylation, (2) CIN, with losses of suppressor genes (APC and TP53) will result in LOH, and mutations with activation of oncogenes (KRAS) 3-MIS, which concerns nonencoding repetitive DNA sequences, is classified as high (MIS-H), low (MIS-L), or stable (MSS). The combination of the 3 pathways results in 5 categories of neoplastic lesions (Table 10), which were classified by Jass.⁵⁷ It is estimated that CIN with MSS accounts for around 77% of cases (including the germline mutation of the APC gene), then carcinogenesis is based on the sequence APC-KRAS-TP53. Chromosome stability with MIS results in inactivation of multiple genes; it occurs in close association with BRAF mutation in around 20% of cases or in the germline mutation of a MMR gene (hMLH1).

Genetic factors involved in the development of polypoid carcinoma

Mutations in epithelial cells. In the normal colorectal mucosa, stem cells are thought to reside at the base of crypts; the Fearon and Vogelstein¹⁵ described the progression from the initial subset of neoplastic cells in the "top-down" direction, which, in spite of some diverging opinions,⁷⁸ is the most accepted theory.^{15,79} In line with the top-down theory, the same group⁷⁹ compared, in the early stage of an adenoma, the molecular characters of cells with a neoplastic morphology at the luminal surface of the crypts and that of cells with a normal morphology at the base of these same crypts. The cells at the top of the crypts often exhibited genetic alterations that were not observed in cells located at the base of the same crypts. The genetically altered cells arise in the upper pole of the crypt, progress down in the crypt, and spread laterally in adjacent crypts. The growth of neoplastic cells with crypt fission ends in a macroscopic lesion.

The traditional sequence described in 1990 by Fearon and Vogelstein,¹⁵ is responsible for the majority of sporadic colorectal cancer. The mutation of the APC tumor suppressor gene on the long arm of chromosome 5 (5q21) is followed by CIN and LOH, ie, loss of segments of chromosomes, and successive mutations of suppressor genes or activation of oncogenes: *Kras* gene on chromosome 12q, *DCC* gene on chromosome 18p, and *TP53* gene on chromosome 17p (Fig. 6). The repetitive nucleotide sequences of DNA in the microsatellites are not modified by mutations, and the tumor is MSS.

Hirata et al⁸⁰ analyzed APC, KRAS, and TP53 gene mutations in 96 cases of primary colorectal cancer and stressed the variable prevalence of associations in altered chromosomes: the combination APC and KRAS occurred in 21.9%; the prevalence of *Kras* and TP53 and of APC and TP53 combinations was 12.5% and 10.4%, respectively; and the combination of APC, *Kras*, and TP53 mutations was the less frequent (6.3%). This variability suggests an interaction between exogenous environmental factors

TABLE 10. Relationship between molecular groups and morphology of neoplastic lesions*

CIMP status	CIN status	MIS status	Inaugural mutation	Related neoplastic lesions	Proportion (%)
High	Stable	MIS-H	BRAF	Serrated lesion; sporadic cancer	12
	Stable	MSS	BRAF	Serrated lesion	8
Low	Unstable	MSS	KRAS	Sporadic adenoma; serrated lesion	20
Negative	Unstable	MSS	KRAS	Sporadic adenoma; FAP; germline mutation	57
	Stable	MIS-H	MLH1	HNPCC; germline mutation	3

MIS-H, High microsatellite instability; MIS-L, low microsatellite instability.

*Colorectal carcinoma develops in 3 distinct pathways: (1) CIMP, which is high, low, or negative, (2) chromosomal instability (CIN) with losses of suppressor genes by LOH, (3) microsatellite instability, which is high (MIS-H), low (MIS-L), or stable (MSS); a combination of the 3 pathways results in 5 categories of neoplastic lesions (see reference 67).

TABLE 11. Mutations that occur in neoplastic and nonneoplastic colorectal lesions*

Mutation	% Serrated pathway			
	% Traditional adenoma	HP polyp (microvesicular)	TSA	Sessile serrated lesion
APC	33	0	0	0
KRAS oncogene	15	15	30	7
BRAF protein-kinase	0.3	75	60	80
CIMP	10	50	80	75

*The APC mutation characterizes the adenomatous pathway to cancer. The BRAF mutation characterizes the serrated pathway and is common to HP nonneoplastic polyps and to serrated adenomas (see references 11, 12, 50, 51, 54, 67).

and the somatic genetic alterations. Hermesen et al⁸¹ stressed the role of specific associations of mutations in the progression of polypoid adenomas to cancer. They compared chromosome alterations in 66 benign and 46 malignant colorectal adenomas. Three distinct combinations are linked to the progression toward cancer: 17p loss and Kras mutation, 8q and 13q gain, and 18q loss and 20q gain.

Genetic instability in epithelial cells. An alternative sequence occurs in up to 20% of cases of sporadic colorectal cancer in relation to the CIMP. Epigenetic methylation and inactivation of hMLH1, one of the MMR genes, results in MIS-H and inactivation of many suppressor genes (p16 and PTEN). The tumors with epigenetic methylation of the DNA are highly correlated with a mutation of the BRAF-kinase encoding gene located on the long arm of chromosome 7 (7q34). This group of MIS tumors offers similarities with neoplastic lesions developed in the serrated pathway, which suggests that the precursor




Figure 6. Adenoma pathway to sporadic colorectal cancer. Two distinct sequences monitor the morphologic steps from low-grade neoplasia to invasive cancer. The first is based on initial APC mutation, CIN, and LOH; DNA microsatellites are stable (MSS). The other sequence is based on CIMP, with methylation and inactivation of hMLH1, a MMR gene, which results in MIS and inactivation of many suppressor genes (eg, p16, PTEN). Note: familial cancer, caused by germline mutations, is linked to the APC sequence in the FAP syndrome and to the CIMP sequence in the HNPCC, in which the germline mutation of one of the MMR gene results in high MIS.

lesion is similar. Kambara et al⁹⁴ screened BRAF mutations in different categories of neoplastic colorectal lesions—serrated adenomas, conventional adenomas, and hereditary and sporadic colorectal cancer—and found that BRAF mutation is more frequent in sessile serrated lesions and in sporadic MIS-H cancers, both of which are associated with DNA methylation. Sporadic MIS-H cancers may originate in sessile serrated lesions rather than in conventional adenomas.

Genetic instability in the stroma. Recent studies suggest that, just as for breast cancer, genetic instability in the stroma may influence the progression of neoplastic colorectal lesions. Ishiguro et al⁹⁵ analyzed, with microsatellites and chromosome 17 markers, the epithelial and stromal compartments of colorectal adenomas for LOH

and instability in the sequences of microsatellites. In epithelial cells, the prevalence of LOH and MIS, which is extremely low in HP polyps, increases with the progression of the alterations in premalignant adenomas and, furthermore, in invasive carcinoma. In the stroma, the prevalence of LOH or MIS does not vary with the progression of neoplasia. Therefore, genetic instability in the stroma is a very early event in the development of colorectal neoplasia. Matsumoto et al⁹⁶ tested MIS with 4 markers in 40 cases of sporadic colorectal cancer: the frequencies of positive MIS in the epithelial and in the stromal compartments were 34% and 41%, respectively. In the epithelial compartment, positive MIS is more frequent in poorly differentiated than in well-differentiated cancer. In the stromal compartment, an opposite variation occurs: positive MIS is more frequent (54%) in well-differentiated cancer (54%) than in poorly differentiated cancers (10%). It is concluded that, rather than being a reaction to epithelial tumoral cells, stromal genetic instability in chromosome 17 markers may control the development and differentiation of the tumor.

Genetic factors involved in the development of nonpolypoid or flat carcinoma

The distinct sequence of genetic events that controls the development of nonpolypoid lesions in the colorectal mucosa is progressively being confirmed with techniques that vary from immunohistochemistry in tissue sections to microdissection and DNA sequencing.^{47,81-89,92} Molecular events that occur in nonpolypoid lesions were analyzed in 3 distinct circumstances: (1) flat adenomas, classified as premalignant lesions, either when including all depressed and nondepressed subtypes or when including only the flat depressed adenomas, (2) LST lesions, which were classified with ambiguity in granular, nongranular, and homogenous subtypes, rather than in subtypes of the Paris classification, (3) flat carcinomas or, more precisely, flat carcinomas that show no remnants of adenoma, which are often called *de novo* cancer. The heterogeneity of early neoplastic lesions in patients with inflammatory bowel disease is beyond the scope of this discussion, in spite of the unusual high proportion of neoplastic areas with a flat morphology.¹⁰⁰⁻¹⁰⁴

Mutations in epithelial cells. In flat adenomas, *Kras* mutations have a lower frequency in flat nonpolypoid lesions than in polypoid lesions, as shown by Yamagata et al⁸⁷; the figures in their study were 23% and 67%, respectively. More precisely, the frequency of *Kras* mutations in depressed adenomas and in polypoid adenomas were estimated in 2 other studies: the figures were at 0% and 31%, respectively, in the study by Umetani et al⁸⁹ and at 8.6% and 25%, respectively, in the study by Morita et al,⁸² restricted to diminutive lesions less than 5 mm in diameter. The frequency of APC mutations has also been estimated in depressed lesions and is lower (7%) in non-

polypoid depressed adenomas than in polypoid lesions (43%), as shown by Umetani et al⁸⁹ in 2000.

In LST lesions, Mukawa et al⁸⁵ compared the frequency of *Kras* mutations in subtypes of LST lesions and found a lower prevalence of the mutation (26.3%) in 19 cases with a nongranular type (which is usually flat) than in 17 cases with a granular type (76.5%). This was confirmed by Hiraoka et al,⁸⁴ who compared *Kras* mutations in LST lesions at least 1 cm in diameter: the prevalence of the mutation was lower (16%) in the flat type with a homogenous surface, than in the more protruding granular type (78%). Takahashi et al⁸⁵ obtained different results when comparing *Kras* mutations in 101 LST lesions, called flat advanced adenomas, and in 68 polypoid advanced adenomas: the prevalence of *Kras* mutations was higher (35%) in LST lesions than in polypoid adenomas (13%). The divergence in the results of these studies may relate to the imprecision in the morphologic classification of LST lesions.

In flat carcinomas (1) in various studies that compared flat carcinomas with polypoid carcinomas, the low frequency of *Kras* mutations is confirmed: the published figures were 11% and 56%,⁸⁹ 0% and 44%,⁸⁸ and 0% and 36%,⁴⁷ respectively, (2) frame-shift mutations of the APC gene do not occur in nonpolypoid carcinomas and occur in 66% of polypoid carcinomas, as shown by Kaneko et al,⁴⁷ (3) mutations of the TP53 gene were analyzed by Fujii et al⁹¹ in 13 cases of early flat cancer: LOH on chromosome 17p locus, near the TP53 gene occurs early and is frequent (77%), genetic heterogeneity is similar to that observed in more advanced polypoid cancer in the preinvasive stages. The prevalence of TP53 mutations in early and flat cancer was also analyzed in European series.⁹⁰⁻⁹³ Mueller et al⁹⁰ compared the frequencies of LOH at the 17p locus near the TP53 gene in 35 cases of early colorectal cancer without residual adenoma (*de novo* cancer) and in 36 cases of superficial (pT1) cancer developed in the adenoma sequence: the prevalences were 73% and 37%, respectively. In conclusion, the more aggressive character of the *de novo* carcinoma is confirmed by the higher rate of LOH at 17p locus with more frequent TP53 mutations.

Genetic instability in epithelial cells and stroma. In advanced carcinomas,⁴⁷ nonpolypoid and polypoid tumors show a similar proportion of MIS. In 99 superficial (early) colorectal carcinomas with invasion of the submucosa, Ogawa et al³⁴ analyzed genetic instability with microsatellite markers from the National Cancer Institute and for chromosome 17 instability. The frequency of epithelial MIS is significantly higher in nonpolypoid (33.3%) than in polypoid superficial cancer (10.4%). In the stroma of the tumor, instability of chromosome 17 markers is higher in nonpolypoid than in polypoid superficial cancers. It is concluded that epithelial and stromal MIS of chromosome 17 markers contributes more to carcinogenesis in nonpolypoid lesions.




Figure 7. Serrated pathway to sporadic colorectal cancer. Two distinct molecular sequences monitor the morphologic steps from nonneoplastic lesions to neoplasia and invasive cancer. Serration is included in both sequences. The first is based on initial BRAF mutation and CIMP with inactivation of hMLH1, which results in MIS. The HP lesion, eventually arises from ACF and is not neoplastic; a sessile serrated lesion is often called sessile serrated adenoma as well; serrated adenoma (SA) is a neoplastic lesion and may progress to cancer. The other sequence, based on early K-ras mutation and CIN, results in a serrated adenoma (SA) which may progress to cancer; the DNA microsatellites are stable (MSS).

Combined chromosomal alterations in flat carcinomas. *Kras* and APC mutations are less frequent in nonpolypoid than in polypoid lesions. The difference was confirmed in various categories of lesions: flat adenomas, depressed flat adenomas, nongranular type of LST lesions, flat carcinomas, and de novo carcinomas. In the majority of studies, flat lesions are considered as a single group, and a specific behavior of depressed lesions is not underlined. Also, chromosomal alterations may be combined to convey a more aggressive behavior of the tumor. The simultaneous and early occurrence of multiple LOH, including 17p, 18p, 18q, and 22q in colorectal flat tumors suggests their classification as a de novo cancer with more aggressive clinical behavior.³⁵ In the Netherlands, Postma et al⁸⁶ analyzed 6 flat adenomas and 12 flat adenocarcinomas, and found higher frequencies of 20q gain and 18q loss than in previously analyzed polypoid neoplastic lesions. Combined alterations in these 2 chromosomal regions were already linked to tumor aggressiveness by the same group.⁸¹ Epithelial MIS is more frequent in nonpolypoid lesions.

Genetic factors involved in hereditary cancer

Hereditary cancer syndromes are caused by germline mutations. In familial adenomatous polyposis (FAP), the colorectal tumor shows MSS and is caused by a dominant germline mutation in the APC gene on chromosome 5q; a clinical syndrome of attenuated FAP is caused by a mutation of a BER (base excision gene, located on chromosome 1p). In the hereditary nonpolyposis colon cancer (HNPCC) syndrome, the tumor with MIS is caused by a dominant

germline mutation of one of the MMR genes, which results in high instability of the repeated sequences of nucleotides in MIS-H and multiple mutations of suppressor genes in the CIMP phenotype.³⁷⁻³⁹

Genetic factors involved in the development of serrated lesions

Mutations with MIS. Serrated lesions cover a spectrum of nonneoplastic and neoplastic lesions and share a persisting serrated pattern of the crypts. The majority of serrated neoplastic lesions show MIS with a MIS-H status. Mutation of the BRAF-kinase gene on chromosome 7q (Fig. 7) and DNA epigenetic methylation are early events in this pathway to neoplasia, and the frequency of this mutation in colorectal polypoid lesions has often been analyzed.^{69,72,94} The methylator phenotype is absent in simple HP lesions and frequent in HP polyposis; the prevalence of this phenotype progressively increases in the continuum that leads to a serrated carcinoma. After the initial BRAF mutation, the molecular events include inactivation through methylation of the MMR gene hMLH1, with MIS-H and successive mutations of suppressor genes. Spring et al⁷² explored the frequency of BRAF mutations in different categories of lesions detected in patients who had colonoscopy: the mutation, rare in adenomas (0.4%), was frequent in the microvesicular type of HP lesion (70%), in sessile serrated lesions (78%), and in TSAs (66%). Kambara et al⁹⁴ analyzed BRAF mutations in patients undergoing colectomy for either colorectal cancer or HP polyposis; a high prevalence was confirmed in sessile serrated lesions and in sporadic colorectal cancer with a MIS-H status. The microvesicular type of the HP lesion is considered the precursor of sessile serrated lesions, which can progress to neoplasia but should not be misclassified as a TSA, which is a neoplastic lesion. Torlakovic et al⁷³ showed that the distribution of cells labeled with Ki-67 is the most helpful feature for the distinction between the 2 categories of lesions: the expression of Ki-67 is irregular and highly variable in sessile serrated lesions and is localized in the ectopic crypts, which characterize the architecture of TSAs. Most likely, sporadic MIS-H cancers originate from sessile serrated lesions as a consequence of the CIMP, which leads to successive mutations of suppressor genes.

Mutations with MSS. An alternative sequence that leads to a serrated carcinoma is based on an initial *Kras* mutation with CIN. Successive mutations of suppressor genes result in a TSA that may progress to a serrated cancer; the DNA microsatellites are MSS in this category of tumor.

ROLE OF ABERRANT CRYPT FOCI ON THE ORIGIN OF COLORECTAL CARCINOMA

Aberrant crypt foci (ACF) are defined as small clusters (2 or more) of enlarged crypts with dilated openings,

which rise above the adjacent mucosa.¹⁰⁵⁻¹¹⁴ ACF can be identified and numbered at the surface of the mucosa with magnification chromoendoscopy, by using indigo carmine solution at 0.2%, or methylene blue solution at 0.01%. The numeration is usually performed with a high-power field, which may vary according to the material used and the investigators, in a 20-cm or 10-cm length of the rectum. The count increases with the age of the patient, just as the risk of colorectal cancer increases.¹¹² The ACF count is not temporally stable, as shown in a study by Schoen et al,¹¹⁴ who identified and counted ACF again, after a 1-year interval, in the rectum: less than half the specific ACF could be reidentified, and more than 50% of the subjects had new ACF. ACF are postulated to represent the monocryptal initial event in the development of neoplastic lesions or serrated lesions in the colorectal mucosa.

Diversity of ACF phenotypes

ACF are classified into 3 categories: (1) HP ACF have a nonserrated morphology, the crypt lumen is round but enlarged, and the mucin content is not increased, (2) HP serrated ACF show a serrated crypt lumen with increased mucin, and (3) neoplastic ACF are less frequent and show enlarged and stratified nuclei. ACF with a neoplastic type can be considered a microadenoma and can have proliferation in the upper part of the crypt, and are more common in FAP than in patients with sporadic colorectal neoplasia. In contrast, the nonneoplastic categories of ACF (called heteroplastic) have proliferation mainly in the lower part of the crypts.

Diversity of ACF genotypes

The distinct sequences that lead to neoplasia across the nonserrated and serrated pathways have been studied after direct polymerase chain reaction (PCR) sequencing of the DNA from isolated ACF with an HP serrated, or neoplastic architecture. BRAF mutations are linked to HPACF with a serrated phenotype, and *Kras* mutations are linked to ACF with a nonserrated phenotype. In the study conducted by Rosenberg et al,¹¹⁰ BRAF mutation was present in 10 of 16 serrated ACF and in only 1 of 33 nonserrated ACF; conversely, *Kras* mutation was present in 3 of 16 serrated ACF and in 14 of 33 nonserrated ACF. Beach et al⁶⁹ confirmed that BRAF mutation was rare in nonserrated neoplasia, did not occur in ACF from patients with hereditary cancer (FAP), and only occurred in 3% of ACF from patients with sporadic colorectal cancers. *Kras* mutation was present in only 4% of ACF from patients with hereditary cancer (FAP) and occurred in 40% of ACF from patients with sporadic colorectal cancers.

ACF and the risk of cancer

The count of ACF in the rectum follows a stepwise progression in patients with a negative colonoscopy, adenomatous polyps, or colorectal cancer, and in the study

conducted by Adler et al,¹⁰⁵ the values of the count of ACF in these 3 categories were $n = 5$, $n = 6.9$, and $n = 9.9$, respectively, and in the study conducted by Takayama et al,¹⁰⁹ the figures were $n = 1$, $n = 5$, and $n = 26.5$, respectively. Kukitsu et al¹¹¹ showed that the number of ACF is higher in patients with ulcerative colitis when a neoplastic lesion is associated. The relationship between the prevalence of ACF in the rectum and the presence of nonpolypoid neoplastic lesions in the proximal portion of the colon was also analyzed. In the study conducted by Hurlstone et al,¹⁰⁶ the mean number of ACF in the rectum was $n = 1$ in patients with a negative colonoscopy, $n = 9$ in those with nonpolypoid adenomas, and $n = 38$ in those with a nonpolypoid cancer in the proximal portion of the colon.

In hereditary cancer, Nucci et al¹¹³ showed that most ACF in patients with a FAP syndrome have a neoplastic morphology, whereas those observed in patients with sporadic colorectal cancer have an HP morphology. In the study conducted by Beach et al,⁶⁹ 91% of ACF from patients with a FAP syndrome had a neoplastic morphology, whereas 87% of ACF from patients with sporadic colorectal cancer were HP. Stevens et al¹⁰⁸ established a relationship between the count of ACF and the familial risk of cancer. The count was lower ($n = 4.4$) in patients without a family history of cancer than in patients with a family history of cancer ($n = 9$) or with a personal history of cancer ($n = 7.5$).

In conclusion, ACF are considered as the earliest and monocryptal precursors of neoplastic lesions in the colon and are postulated as valuable biomarkers for the risk of colorectal cancer. They could prove helpful in surveillance protocols of patients at increased risk of cancer, including those with inflammatory bowel disease. In addition, genetic alterations in ACF differ in the serrated and nonserrated neoplasia.

ENDOSCOPIC FEATURES OF NONPOLYPOID LESIONS

Endoscopic prevalence of superficial neoplastic lesions

The prevalence of superficial lesions detected during complete colonoscopy in the colorectal mucosa of asymptomatic patients is high in Japan.^{115,116} In a study conducted at the National Cancer Center in Tokyo in 2004 by the Research Cancer Center for Prevention and Screening,¹¹⁶ the prevalence of neoplastic lesions was 60% in 2968 patients. In Western countries, the figures depend on the recourse to high-resolution endoscopy and image processing during colonoscopy. In the United States, Imperiale et al¹¹⁷ proceeded to colonoscopic screening in 906 patients: the percentage of patients with adenoma was 10%. A higher proportion (37.5%) was found in 3121 patients by Lieberman et al,¹¹⁸ and

TABLE 12. Superficial neoplastic colorectal lesions and numbers and proportion of depressed nonpolypoid types: comparison between Japanese and Western series*

Study	No. all lesions	No. flat and depressed lesions	
		0-Ic, 0-Ic + IIa, 0-IIa + IIc (%)	0-IIa + IIc (%)
Okuno et al, ¹²⁴ multicenter study (8 groups), Japan	66,670	1291 (1.9)	
Togashi et al, ¹²⁵ Japan	5408	152 (2.8)	
National Cancer Center, 2004, Tokyo, Japan	4303	31 (0.7)	
Fujii et al, ¹³⁰ U.K.	68	2 (2)	
Rembacken et al, ¹³² U.K.	446	4 (0.9)	
Hurlstone et al, ¹³¹ U.K.	745	51 (6.8)	
Kiesslich et al, ⁵ Germany	105	2 (2)	
Tsuda et al, ¹³³ Sweden	973	14 (1.4)	
Soetikno et al, ¹³⁷ U.S.	1535	18 (1.2)	

*The proportion of depressed (0-Ic) lesions that occur in the Western series is similar to that observed in the Japanese series. Misclassification between some subtypes (0-Ic vs 0-IIa and 0-IIb vs 0-IIa) may occur in the Western series. In all series, lesions with intramucosal or submucosal cancer are included; cancer with invasion beyond submucosa is not included.

units from the Akita and Yokohama hospitals (1985-2007), the proportion of nonpolypoid lesions was high, with 10,948 nonpolypoid lesions (42%) of 25,862 superficial neoplastic lesions detected. In a similar analysis from the endoscopy unit of the Hiroshima University Hospital (1991-2007), the proportion of nonpolypoid lesions was still high, with 2711 nonpolypoid lesions (27%) of 12,811 superficial neoplastic lesions detected.

In Western countries, the finding of flat or depressed nonpolypoid neoplastic lesions in the population was acknowledged in recent years,¹²⁶⁻¹³⁰ and the proportions of polypoid and nonpolypoid lesions were also analyzed or reviewed in some studies.¹³¹⁻¹³⁷ In the United States, O'Brien et al²⁶ revised the classification of data in the National Polyp Study and estimated the proportion of nonpolypoid lesions at 31.4%. In the recent study of Soetikno et al,¹³⁷ the overall prevalence of nonpolypoid neoplastic lesions was 9.35%; in this series, nonpolypoid neoplastic lesions, irrespective of their size, were more likely to contain carcinoma than polypoid lesions. Saitoh et al¹³⁵ detected, with dye-assisted colonoscopy, flat and depressed lesions in 22.7% of 211 patients; depressed lesions were also more likely to show invasive cancer (4.5%) than were polypoid lesions (0%). Lieberman et al¹³⁴ analyzed the yield of recurrent neoplastic lesions that occurred after an interval of 5.5 years but did not describe the morphology of the lesions. In Europe, the proportions of nonpolypoid lesions were estimated at 27.3% by Rembacken et al,¹³² 40.9% by Hurlstone et al,¹³¹ and only at 8.4% by Tsuda et al.¹³³

even higher figures (67%) were displayed by Rex and Helbig¹¹⁹ in a recent cohort of 434 patients aged 50 years or older.

Follow-up studies give an indication about the natural evolution of polypoid adenomas that were not removed after detection. In Denmark, a prospective follow-up study was conducted over 3 years in 58 patients undergoing annual colonoscopy, whereas all polyps smaller than 10 mm were maintained.¹²⁰⁻¹²² In this study, adenomas and HP polyps smaller than 5 mm showed a tendency to net growth, whereas lesions in the size range 5 to 9 mm showed a tendency to net regression.¹²⁰⁻¹²² In the United States, the "observed" incidence of adenomas and colorectal cancers that occurred in the National Polyp Study during surveillance procedures was compared with the simulated outcomes of a MISCAN-COLON model.¹²³ The discordance between the high incidence of adenomas detected and the low incidence of colorectal cancer suggest that the rise of new adenomas is accompanied by the regression of many others.

Proportions of polypoid and nonpolypoid lesions

In Japan, the proportions of polypoid and nonpolypoid superficial lesions of the colorectal mucosa were estimated in very large series^{124,125} collected during a prolonged period (15-20 years). In the endoscopy

Endoscopic prevalence of depressed nonpolypoid lesions

The attention is drawn, in spite of their relative rarity, on depressed lesions (0-Ic, 0-Ic + IIa, or 0-IIa + IIc), because, even when small, they are more advanced in their progression to cancer. In published data from Japan and from Western countries, these lesions represent 1% to 6% of the total count of superficial colorectal lesions, as shown in various series (Table 12). In Japan and, specifically, in the large series from the Akita and Yokohama Hospitals, all subtypes of premalignant and malignant depressed lesions (0-Ic, 0-Ic + IIa, and 0-IIa + IIc) represent 2.3% of all superficial lesions (polypoid and nonpolypoid) and 5.5% of all nonpolypoid types (585 of 10,948) (Table 13). The proportions for the series of the Hiroshima University Hospital are 2.2% of all lesions and 10.5% of nonpolypoid lesions (285 of 2711) (Table 14).

The relative rarity of depressed lesions is still confirmed when the count is restricted to early cancer. In the statistics of the national cancer screening in Japan (2004-2005), 0-Ic lesions represent 8.7% (367/4180) of all cases of early cancer (Table 15); the lesions were detected in patients positive for the immunologic fecal blood test. The

TABLE 13. Morphology of superficial neoplastic lesions and the proportion of Ca in the submucosa: results in 25,762 lesions from the series of the endoscopy unit at Akita and Yokohama Northern Hospitals, Japan, for the period April 1985 through July 2007*

	No. lesions				
	Total	Up to 5 mm	6-10 mm	11-19 mm	≥ 20 mm
Polypoid, 0-I, Ips, Is					
No. all lesions	14,814	7046	5582	1863	323
No. submucosal Ca only (%)	358 (2.4)	0 (0)	72 (1.3)	192 (10.3)	94 (29.1)
Nonpolypoid, 0-IIa, IIb					
No. all lesions	10,363	7583	1436	929	415
No. submucosal Ca only (%)	138 (1.3)	2 (0.03)	5 (0.35)	50 (5.3)	81 (19.5)
Nonpolypoid, depressed, all 0-IIc					
No. all lesions	585	263	172	127	23
No. submucosal Ca only (%)	210 (35.9)	22 (8.4)%	75 (43.6)	93 (73.2)	20*(87.0)
Total superficial neoplastic lesions	25,862	14,892	7190	2919	761

Ca, Cancer.

*Proportions of polypoid, nonpolypoid not depressed and polypoid depressed lesions were 57%, 40%, 2.3%, respectively. Submucosal invasion occurs in 706 lesions, of which 348 are nonpolypoid. The number of nonpolypoid depressed lesions is small, but the proportion of Ca with submucosal invasion is high.

TABLE 14. Morphology of superficial neoplastic lesions and proportion of cancer in the submucosa: results in 12,811 lesions from the series of the endoscopy unit at the Hiroshima University Hospital during the period January 1991 through November 2007*

	No. lesions				
	Total	Up to 5 mm	6-10 mm	11-19 mm	≥ 20 mm
Polypoid (0-I, Ips, Is)					
No. all lesions	10,100	5846	2606	1211	437
No. submucosal Ca only (%)	177 (0.7)	4 (0.07)	41 (1.6)	71 (5.8)	61 (14)
Nonpolypoid (0-IIa, IIb)					
No. all lesions	2426	1050	746	455	175
No. submucosal Ca only (%)	51 (2.1)	0 (0)	13 (1.7)	25 (5.4)	13 (7.4)
Nonpolypoid, depressed (all 0-IIc)†					
No. all lesions	285	100	96	64	25
No. submucosal Ca only (%)	77 (27)	6 (6)	17 (17.7)	34 (53.4)	20 (80.0)
Total superficial neoplastic lesions	12,811	6996	3448	1730	637

*Proportions of polypoid, nonpolypoid not depressed, and polypoid depressed lesions are 78.8%, 18.9%, 2.2%, respectively. Submucosal invasion occurs in 510 lesions, of which 256 are nonpolypoid. The number of nonpolypoid and depressed lesions is small, but the proportion of cancer with submucosal invasion is high.

†LST lesions type LST-granular (n = 510) are not included; pseudodepressed lesions type LST-nongranular are included in nonpolypoid depressed lesions.

proportion is slightly higher in the study conducted at Ji-chi University, where 0-IIc lesions represent 10.4% of all cases of early cancer (39/373) (Table 16).

Distribution of subtypes in LST lesions

In Japan, the distribution of the morphologic subtypes of 1751 lesions classified as LST, is shown in a cumulative

analysis of the experience of the endoscopy units of Akita and Yokohama Hospitals and of the National Cancer Center in Tokyo (S. Kudo, T. Fujii, unpublished data, 2008): 889 LST lesions were classified as granular, and 862 LST lesions were classified as nongranular. The sizes of the lesions were less than 20 mm in 1144 and 20 mm or greater in 607 (Table 17). In the recent experience at the

TABLE 15. Morphology of superficial colorectal cancer and proportion of submucosal invasion: results of the National Colorectal Cancer Screening in Japan in 187 of 207 selected sites for the period 2004 to 2005*

	Subtype 0	No.	
		Ca m and sm	Ca sm (%)
Polypoid	Ip/lsp	2522	465 (18.4)
	Is	637	198 (31.0)
Nonpolypoid	Ila	645	196 (30.0)
	Ila+ Ilc	271	181 (66.7)
	Ilb and Ilc	96	54 (56.2)
Excavated	III	9	2 (22.2)

Ca, Cancer.

*Total number of superficial Ca m or sm detected and classified in subtypes 0 is 4180. Total number of Ca sm is 1096. The proportion of submucosal invasion is much higher in the 2 groups of type 0-IIc lesions.

Yokohama Hospital (S. Kudo, H. Kashida, unpublished data, 2008) of 699 LST lesions (Table 18), the proportion of LST lesions with a nongranular and pseudodepressed morphology is 9.8% (69/699). This subtype of LST lesion corresponds to a more advanced stage in the progression to cancer. When compared with polypoid neoplastic lesions, LST lesions were characterized by different molecular markers.^{83,138,139}

Proportions of adenomatous and serrated lesions

In Japan, the size and location in the colon and rectum of HP lesions were analyzed in the National Cancer Center Hospital East, Chiba,⁵⁵ in 226 patients who harbored such lesions at colonoscopy: the majority of HP lesions (3020/3060) were less than 6 mm in diameter and were located in the distal portion of the colon (95%); only 5% of these lesion were in the proximal portion of the colon. In this series, which excluded patients with HP polyposis, mid-sized HP lesions (6-10 mm) were rare (28/3060) and were located either in the distal portion (58%) or in the proximal portion (42%) of the colon, whereas lesions 10 mm and larger were extremely rare (2/3060) and were located in the proximal portion of the colon.

In the United States, a multicenter study assessed the proportions of adenomatous and serrated lesions during colonoscopies performed in the Minnesota Community Practice study during the period February 1 through December 31, 2007 (J. Allen, unpublished data, 2008). Among 15,015 lesions detected, 8897 were classified as adenomatous (58%) and 5229 were serrated (37%) (the others were not analyzable with precision). Among adenomatous lesions, 1413 corresponded to advanced neoplasia (19.1%) (tubular adenoma at least 10 mm, villous adenoma, HGIN, or cancer). Among serrated lesions, 3742

were classified as HP, and 1688 were classified as sessile serrated lesions.

A similar study was conducted by Spring et al⁷² in 414 superficial lesions detected during colonoscopies at the Royal Brisbane Hospital, Australia. The proportions of adenomatous and serrated lesions were 60% and 40%, respectively. Of the 248 adenomatous lesions, 237 were found to be tubular and 11 tubulovillous. Among 166 serrated lesions, there were 120 HP, 36 sessile serrated lesions, 3 mixed polyps, and 7 TSAs.

ENDOSCOPIC FEATURES OF MALIGNANT NONPOLYPOID LESIONS

Cancer in polypoid and nonpolypoid lesions

The proportion of cancer with invasion of submucosa was analyzed in relation to morphology in endoscopic series from Japan. At the Akita and Yokohama Northern Hospitals (Table 13), the proportion of cancers with invasion of the submucosa was very high in depressed nonpolypoid lesions: 35.9% (210 of 585 lesions). In the series of the Hiroshima University Hospital (Table 14), the figure was also very high for the same category of lesions: 27% (77 of 285 lesions). In contrast, in both series, the proportions of cancer with invasion of the submucosa were very low in polypoid lesions: 2.4% and 0.7%, respectively. In the statistics of the national cancer screening in Japan for the period 2004 to 2005, the proportion of cancer with invasion of the submucosa in depressed nonpolypoid lesions with early cancer was also high and was estimated at 64% (Table 15). A study of the depth of invasion in the submucosa was conducted at the pathology department of the National Cancer Center, Tokyo, Japan, (T. Shimoda, unpublished data, 2008) in 146 superficial colorectal cancers with submucosal invasion. The analysis included polypoid and nonpolypoid early cancers. The depth of invasion was estimated from the muscularis mucosae and was classified as sm1, if invasion was less than 1000 μ m, and sm2, if invasion was more than 1000 μ m.

In 87 polypoid carcinomas, sm1 invasion occurred in 52.9%, and the average size of sm1 tumors was 21.5 mm; sm2 invasion occurred in 47.1%, and the average size of sm2 tumors was 27.7 mm. In 59 nonpolypoid carcinomas, sm1 invasion of the submucosa occurred in 27.1%, and the average size of sm1 tumors was 12.2 mm; sm2 invasion occurred in 72.9%, and the average size of the tumor was 14.8 mm. It was concluded that nonpolypoid lesions with invasion of the submucosa show a higher proportion of massive invasion and are smaller than polypoid lesions. In Western countries, the proportion of cancer (without distinction between intramucosal or submucosal invasion) was analyzed in relation to morphology and was also high for depressed lesions, and varied from 11.7% to 50% in several endoscopic series. In contrast, the

TABLE 16. Morphology of superficial neoplastic lesions and proportion of Ca (mucosal or submucosal) in each category: comparison between Japanese and Western series*

	No. neoplastic lesions and proportion of Ca					
	All polypoid lesions		All nonpolypoid lesions (0-Ia, IIb, IIc)		Depressed lesions (all IIc)	
	No. lesions	No. lesions with Ca (%)	No. lesions	No. lesions with Ca (%)	No. lesions	No. lesions with Ca (%)
Togashi et al, ¹²⁵ Japan	4279	298 (6.9)	1129	75 (6.6)	152	39 (25.6)
Rembacken et al, ¹³² U.K.	327	2 (0.6)	119	6 (5.1)	4	2 (50)
Hurlstone et al, ¹³¹ U.K.	470	4 (0.8)	275	8 (2.9)	51	6 (11.7)
Tsuda et al, ¹³³ Sweden	907	11 (1.2)	66	5 (7.5)	14	4 (22)
Soetikno et al, ¹³⁷ U.S.	1308	13 (1)	227	15 (6.6)	18	6 (33)

Ca, Cancer.

*Cancer is either intramucosal or with submucosal invasion; Ca with invasion beyond the submucosa is not included.

TABLE 17. Predictive value of the morphology of LST of neoplastic lesions for Ca in the submucosa: subtype and size of LST in the series from the Akita and Yokohama Hospitals (n = 1209) in the period April 1985 through July 2007, and of the National Cancer Center, Tokyo (n = 542) during the period January 1999 through December 2003*

LST	< 20 mm		≥ 20 mm	
	No.	No. Ca in submucosa (%)	No.	No. Ca in submucosa (%)
Granular				
Akita-Yokohama	284	4 (1.4)	314	41 (13.0)
Tokyo	202	9 (4.4)	89	15 (16.8)
Nongranular				
Akita-Yokohama	426	27 (6.4)	185	40 (21.6)
Tokyo	232	25 (11)	19	8 (42)

Ca, Cancer.

*The risk of cancer with submucosal invasion increases with the size of the lesion.

proportion of cancer in polypoid lesions was very low and varied from 0.6% to 1.2% (Table 16).

Cancer in LST lesions

The risk of cancer in LST lesions increases with size and varies with morphologic subtypes. At the Akita and Yokohama Hospitals during the period from April 1985 to July 2007 (S. Kudo, H. Kashida, unpublished data, 2008), 1209 LST lesions were distributed according to their size in 3 groups: 10 to 19 mm, 20 to 29 mm, and 30 mm and larger;

the proportions of cancer with invasion of the submucosa were 4.4%, 13.1%, and 20.6%, respectively. The risk of cancer varied with the subtype of the LST lesion and was higher in the granular with mixed nodules and in the nongranular and pseudodepressed subtypes. In 181 lesions of the subtype granular with mixed nodules, the proportions of cancer with submucosal invasion in the 3 groups of increasing size, 10 to 19 mm, 20 to 29 mm, and 30 mm and larger, were 7.1%, 20.4%, and 38.0%, respectively, and, in 123 lesions of the subtype nongranular and pseudodepressed, the figures were 12.5%, 32.4%, and 83.3%, respectively.

Cancer in serrated lesions

The malignant potential of serrated adenomas is lower than that of traditional adenomas. A study conducted by Song et al⁶⁰ in Korea compared 124 serrated adenomas with serration of 20% of crypts and cytologic alterations of nuclei with 419 traditional adenomas. The incidence of HGIN or carcinoma was lower (3.2%) in serrated adenomas than in traditional adenomas (9.3%). Although most sessile serrated lesions never progress to cancer, some of them with a large diameter in the proximal portion of the colon may progress rapidly to a serrated carcinoma.⁷¹ Large lesions in the proximal portion of the colon with a preponderant nonpolypoid pattern at endoscopy deserve special attention with respect to the early detection of serrated cancer and its precursors. The broad categories of large lesions located at this level include sessile serrated lesions, as well as precursors of nonserrated cancer, such as flat or slightly elevated adenomas and LST lesions.

The proportions of serrated and nonserrated cancer can be evaluated because colorectal cancer, developed in a serrated lesion, shows some distinct characteristics in addition to specific genetic markers and some MIS.